Clinical Trial Detail

NCT ID NCT02823990
Title TG4010 and Nivolumab in Patients With Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors University of California, Davis
Indications

non-small cell lung carcinoma

Therapies

MVA-MUC1-IL2 vaccine + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST